9 completed. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 3 | Completed 3 |
Follow this drug Literature Review of JNJ-42165279 trials Research Report on JNJ-42165279
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder JNJ-42165279, Placebo - Autism Spectrum Disorder | Phase 2 | Completed | Janssen Research & Development, LLC | 78 | 2018-11-07 | 2025-04-23 |
| A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants JNJ-42165279, Placebo - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 12 | 2018-06-12 | 2025-04-27 |
| An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress JNJ-42165279, Placebo - Depressive Disorder, Anxiety | Phase 2 | Completed | Janssen Research & Development, LLC | 161 | 2015-10-07 | 2025-04-29 |
| A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder JNJ-42165279, Placebo - Phobic Disorders | Phase 2 | Completed | Janssen Research & Development, LLC | 150 | 2015-06-11 | 2025-04-29 |
| A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279 JNJ-42165279, 11C-MK-3168 - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 15 | 2014-02-01 | 2015-09-28 |
| A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Participants JNJ-42165279, Itraconazole - Healthy | Phase 1 | Completed | Janssen Pharmaceutica N.V., Belgium | 16 | 2014-01-01 | 2014-04-23 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants JNJ-42165279 50 mg, JNJ-42165279 100 mg, JNJ-42165279 30 mg - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 40 | 2013-10-01 | 2014-12-03 |
| The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers JNJ-42165279 (100 mg), Placebo - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 43 | 2013-08-01 | 2014-10-15 |
| A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants JNJ-42165279 2.5 - 500 mg oral, Placebo, JNJ-42165279 100 mg oral - Healthy Volunteers, Pharmacokinetics | Phase 1 | Completed | Janssen-Cilag International NV | 29 | 2011-08-01 | 2017-07-06 |
Anxiety Disorders (2) · Autism Spectrum Disorder (1) · Depression (1) · Depressive Disorder (1) · Depressive Disorder, Major (1) · Phobia, Social (1) · Phobic Disorders (1)
Janssen Research & Development, LLC (7) · Janssen Pharmaceutica N.V., Belgium (1) · Janssen-Cilag International NV (1)
United States (5) · Belgium (4) · Australia (1) · Canada (1) · Moldova (1) · Russia (1) · Spain (1) · Ukraine (1) · United Kingdom (1)
2014 (1), 2015 (1)